) Inhibitor Screening Elisa Kit.

Human IgG Subclass Screening Kit

IM50 1 kit (1 ml of each antibody)
EUR 1179.6
Description: Human IgG Subclass Screening Kit by Cygnus Technologies is available in Europe via Gentaur.

Human IgG antibody Laboratories manufactures the ) inhibitor screening elisa kit. reagents distributed by Genprice. The ) Inhibitor Screening Elisa Kit. reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact inhibitor elisa. Other ) products are available in stock. Specificity: ) Category: Inhibitor Group: Screening Elisa

Human Enolase ? Inhibitor Screening Kit (Colorimetric)

each
EUR 744

CBX1 Inhibitor Screening Assay Kit

384 rxns.
EUR 535
Description: The CBX1 Inhibitor Screening Assay Kit is designed to measure the inhibition of CBX1 binding to its substrate. The kit comes in a convenient AlphaLISA® format, with enough biotinylated peptide substrate, assay buffer, detection buffer and purified GST-tagged CBX1 chromodomain to perform a total of 384 enzyme reactions. The key to the kit is the specific binding of the CBX1 chromodomain to the methylated-peptide substrate. With this kit, only three simple steps on a microtiter plate are required. First, a sample containing CBX1 and an inhibitor of choice is incubated with the biotinylated substrate for one hour. Next, acceptor beads are added, then donor beads, followed by reading the Alpha-counts.

USP7 Inhibitor Screening Assay Kit

96 rxns.
EUR 820
Description: The USP7 Inhibitor Screening Assay Kit is designed to measure USP7 activity for screening and profiling applications. The USP7 Inhibitor Screening Assay Kit comes in a convenient format, with a 96-well plate, fluorogenic, ubiquitinated substrate, assay buffer, and purified USP7 enzyme for 96 enzyme reactions. USP7 is incubated with a sample containing assay buffer and Ub-AMC Substrate, and then the plate is read, measuring fluorescence using a fluorescence reader.

CD39 Inhibitor Screening Assay Kit

96 rxns.
EUR 890
Description: The CD39 Inhibitor Screening Assay Kit is designed to measure CD39 activity for screening and profiling applications. The CD39 assay kit comes in a convenient 96-well format, with purified recombinant CD39 enzyme, ATP, CD39 assay buffer, and Colorimetric detection reagent for 96 enzyme reactions. In addition, the kit includes the CD39 inhibitor POM-1 for use as an inhibitor control.

KMO Inhibitor Screening Assay Kit

96 rxns.
EUR 790
Description: The Kynurenine 3-Monooxygenase (KMO) Inhibitor Screening Assay Kit is designed to measure human KMO enzyme inhibition. The kit comes in a convenient format, with enough reaction solution and enzyme to perform a total of 400 reactions. The KMO Inhibitor Screening Assay Kit is simple to use. Recombinant hKMO is mixed with inhibitors and the reaction is initiated through addition of the substrates NADPH and L-Kynurenine. After a room temperature incubation, activity is determined by measuring the absorption of the reaction product at λ=412 nm. The UV absorption signal correlates with the amount of NADPH remaining in the reaction.

KMO Inhibitor Screening Assay Kit

384 rxns.
EUR 1070
Description: The Kynurenine 3-Monooxygenase (KMO) Inhibitor Screening Assay Kit is designed to measure human KMO enzyme inhibition. The kit comes in a convenient format, with enough reaction solution and enzyme to perform a total of 400 reactions. The KMO Inhibitor Screening Assay Kit is simple to use. Recombinant hKMO is mixed with inhibitors and the reaction is initiated through addition of the substrates NADPH and L-Kynurenine. After a room temperature incubation, activity is determined by measuring the absorption of the reaction product at λ=412 nm. The UV absorption signal correlates with the amount of NADPH remaining in the reaction.

Kynureninase Inhibitor Screening Assay Kit

100 rxns.
EUR 830
Description: The Kynureninase (KYNU) Inhibitor Screening Assay Kit is designed to measure human KYNU enzyme inhibition. The kit comes in a convenient format, with enough reaction solution and enzyme to perform a total of 100 reactions. The KYNU Inhibitor Screening Assay Kit is simple to use. Inhibitor and enzyme are mixed and the reaction is initiated through addition of the substrate 3-hydroxy-DL-kynurenine (3-HK). After a room temperature incubation, activity is determined by measuring the fluorescence of the reaction product (ex. 315 nm, em. 415 nm).

Screening Elisa information

PD-L1 : PD-1 [Biotinylated] Inhibitor Screening ELISA Kit

EP-133 96tests
EUR 706.2
Description: Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.

PD-L1 [Biotinylated] : B7-1 Inhibitor Screening ELISA Kit

EP-134 96tests
EUR 706.2
Description: Programmed death molecule 1 and its ligand (PD-1/PD-L1) are a pair of negative immune costimulatory molecules. Under normal circumstances, the combination of PD-L1 on tissue cell surface and PD-1 on lymphocyte surface can inhibit lymphocyte function and induce apoptosis of activated lymphocyte, thus playing an autoimmune tolerance role. However, pD-L1 is also expressed on the surface of various tumor cells. Pd-l1 expressed by tumor cells can bind to PD-1 on the surface of corresponding lymphocytes, inhibit the function of lymphocytes and the release of cytokines, and induce apoptosis of lymphocytes, leading to immune escape of tumor cells. Therefore, blocking the PD-1/PD-L1 pathway can enhance lymphocyte activity to achieve the effect of tumor immunotherapy.

PD-1 : PD-L2 [Biotinylated] Inhibitor Screening ELISA Kit

EP-154 96tests
EUR 706.2
Description: Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.

PD-L1 [Biotinylated] : PD-1 Inhibitor Screening ELISA Kit

EP-158 96tests
EUR 706.2
Description: Immune checkpoint pathway is a focal point of today’s cancer research. PD-1 is one of the best characterized checkpoint proteins. The binding between PD-1 and its ligand PD-L1 suppresses T-cell activation and allows cancer cells to escape from body’s immune surveillance. Therefore, the pharmaceutical inhibition of PD-1 or its ligand has been considered a promising strategy by many oncologists.

OX40 [Biotinylated] : OX40 Ligand Inhibitor Screening ELISA Kit

EP-162 96tests
EUR 706.2
Description: Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

B7-1 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit

EP-116 96tests
EUR 706.2
Description: Cytotoxic T lymphocyte associated ANTIgen-4 (CTLA-4), also known as CD152, is a kind of leukocyte differentiation antigen and a transmembrane receptor on T cells, sharing B7 ligand with CD28. The binding of CTLA-4 with B7 induces T cells to be non-reactive and participates in the negative regulation of immune response. The recombinant CTLA-4 Ig can effectively and specifically inhibit cellular and humoral immune responses in vivo and in vitro, and has significant therapeutic effects on transplant rejection and various autoimmune diseases with very low toxicity. It is considered as a promising new immunosuppressive drug at present.

B7-2 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit

EP-117 96tests
EUR 706.2
Description: Cytotoxic T lymphocyte associated ANTIgen-4 (CTLA-4), also known as CD152, is a kind of leukocyte differentiation antigen and a transmembrane receptor on T cells, sharing B7 ligand with CD28. The binding of CTLA-4 with B7 induces T cells to be non-reactive and participates in the negative regulation of immune response. The recombinant CTLA-4 Ig can effectively and specifically inhibit cellular and humoral immune responses in vivo and in vitro, and has significant therapeutic effects on transplant rejection and various autoimmune diseases with very low toxicity. It is considered as a promising new immunosuppressive drug at present.

CTLA-4 [Biotinylated] : B7-1 Inhibitor Screening ELISA Kit

EP-125 96tests
EUR 706.2
Description: Cytotoxic T lymphocyte associated ANTIgen-4 (CTLA-4), also known as CD152, is a kind of leukocyte differentiation antigen and a transmembrane receptor on T cells, sharing B7 ligand with CD28. The binding of CTLA-4 with B7 induces T cells to be non-reactive and participates in the negative regulation of immune response. The recombinant CTLA-4 Ig can effectively and specifically inhibit cellular and humoral immune responses in vivo and in vitro, and has significant therapeutic effects on transplant rejection and various autoimmune diseases with very low toxicity. It is considered as a promising new immunosuppressive drug at present.

CTLA-4 [Biotinylated] : B7-2 Inhibitor Screening ELISA Kit

EP-126 96tests
EUR 706.2
Description: Cytotoxic T lymphocyte associated ANTIgen-4 (CTLA-4), also known as CD152, is a kind of leukocyte differentiation antigen and a transmembrane receptor on T cells, sharing B7 ligand with CD28. The binding of CTLA-4 with B7 induces T cells to be non-reactive and participates in the negative regulation of immune response. The recombinant CTLA-4 Ig can effectively and specifically inhibit cellular and humoral immune responses in vivo and in vitro, and has significant therapeutic effects on transplant rejection and various autoimmune diseases with very low toxicity. It is considered as a promising new immunosuppressive drug at present.

IL-5 [Biotinylated] : IL-5Rα Inhibitor Screening ELISA Kit

EP-128 96tests
EUR 652.7
Description: Interleukin (IL)-5 is produced and secreted by T cells and mast cellsa critical,and is the important regulator of eosinophils and a therapeutic target for asthma. The pharmaceutical inhibition of IL-5 has been shown to reduce eosinophil counts and ameliorate asthmatic symptoms in studies on animal models of allergy as well as in human clinical trials. There are currently three commercially available IL-5 inhibitors in the United States. These include reslizumab (trade name Cinqair), benralizumab (trade name Fasenra), and mepolizumab (trade name Nucala). All three medications have been approved by the FDA for the treatment of severe eosinophilic asthma.

IL-4 [Biotinylated] : IL-4Rα Inhibitor Screening ELISA Kit

EP-132 96tests
EUR 652.7
Description: Interleukin-4, is a cytokine that induces differentiation of naive helper T cells (Th0 cells to Th2 cells). In the presence of IL-4 and IL-13, cytokines that are produced in a Th-2 type response, particularly during allergy and parasitic infections, macrophages become differentially activated, And this cytokine is a ligand for interleukin 4 receptor. The interleukin 4 receptor also binds to IL13, which may contribute to many overlapping functions of this cytokine and IL13. STAT6, a signal transducer and activator of transcription, has been shown to play a central role in mediating the immune regulatory signal of this cytokine.

IL-4Rα [Biotinylated] : IL-4 Inhibitor Screening ELISA Kit

EP-142 96tests
EUR 652.7
Description: Interleukin-4, is a cytokine that induces differentiation of naive helper T cells (Th0 cells to Th2 cells). In the presence of IL-4 and IL-13, cytokines that are produced in a Th-2 type response, particularly during allergy and parasitic infections, macrophages become differentially activated, And this cytokine is a ligand for interleukin 4 receptor. The interleukin 4 receptor also binds to IL13, which may contribute to many overlapping functions of this cytokine and IL13. STAT6, a signal transducer and activator of transcription, has been shown to play a central role in mediating the immune regulatory signal of this cytokine.

TNF-alpha [Biotinylated] : TNFR1 Inhibitor Screening ELISA Kit

EP-143 96tests
EUR 706.2
Description: Tumor Necrosis Factor (TNF), also known as TNFα, is a kind of cytokine that can kill tumor cells directly and has no obvious cytotoxicity to normal cells. TNF is a cell signaling protein involved in systemic inflammation, and it is one of the cytokines that constitute the acute phase response. It is produced primarily by activated macrophages, but most other immune cells, such as CD4+ lymphocytes, NK cells, neutrophils, mast cells, eosinophils, and neurons in the nervous system can also produce it.

TNF-alpha [Biotinylated] : TNFR2 Inhibitor Screening ELISA Kit

EP-147 96tests
EUR 706.2
Description: Tumor necrosis factor alpha (TNFα) is a cytokine produced primarily by monocytes and macrophages. It is found in synovial cells and macrophages in the tissues.The primary role of TNFα is in the regulation of immune cells. TNFα is able to induce apoptotic cell death, to induce inflammation, and to inhibit tumorigenesis and viral replication. Dysregulation of TNFα production has been implicated in a variety of human diseases, including major depression, Alzheimer's disease and cancer. Recombinant TNFα is used as an immunostimulant under the INN tasonermin. TNFα can be produced ectopically in the setting of malignancy and parallels parathyroid hormone both in causing secondary hypercalcemia and in the cancers with which excessive production is associated.

CD47 [Biotinylated] : SIRP alphaV2 Inhibitor Screening ELISA Kit

EP-152 96tests
EUR 706.2
Description: CD47 is a transmembrane protein, a cell surface glycoprotein molecule belonging to the immunoglobulin superfamily that binds to a variety of proteins, including integrins, thrombospondin 1, and signal regulatory protein-α (SIRPα). In recent years, accumulating data have demonstrated that the CD47-SIRPαV2 axis is a key immune checkpoint in different cancers, including hematological malignancies, similar to PD-1/PD-L1 in solid tumors. CD47-SIRPαV2 blockade has become a next-generation immune checkpoint blocking strategy for various malignancies after PD-1/PD-L1.

TNF-alpha : TNFR2 [Biotinylated] Inhibitor Screening ELISA Kit

EP-161 96tests
EUR 706.2
Description: Tumor necrosis factor alpha (TNFα) is a cytokine produced primarily by monocytes and macrophages. It is found in synovial cells and macrophages in the tissues.The primary role of TNFα is in the regulation of immune cells. TNFα is able to induce apoptotic cell death, to induce inflammation, and to inhibit tumorigenesis and viral replication. Dysregulation of TNFα production has been implicated in a variety of human diseases, including major depression, Alzheimer's disease and cancer. Recombinant TNFα is used as an immunostimulant under the INN tasonermin. TNFα can be produced ectopically in the setting of malignancy and parallels parathyroid hormone both in causing secondary hypercalcemia and in the cancers with which excessive production is associated.

KMO Inhibitor Screening Assay Kit

79513-1 96 rxns.
EUR 790
Description: The Kynurenine 3-Monooxygenase (KMO) Inhibitor Screening Assay Kit is designed to measure human KMO enzyme inhibition. The kit comes in a convenient format, with enough reaction solution and enzyme to perform a total of 400 reactions. The KMO Inhibitor Screening Assay Kit is simple to use. Recombinant hKMO is mixed with inhibitors and the reaction is initiated through addition of the substrates NADPH and L-Kynurenine. After a room temperature incubation, activity is determined by measuring the absorption of the reaction product at λ=412 nm. The UV absorption signal correlates with the amount of NADPH remaining in the reaction.